TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab

Stefan Glück, Jeffrey S. Ross, Melanie Royce, Edward F. McKenna, Charles M. Perou, Eli Avisar, Lin Wu
  • Breast Cancer Research and Treatment, March 2011, Springer Science + Business Media
  • DOI: 10.1007/s10549-011-1412-7

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1007/s10549-011-1412-7

The following have contributed to this page: Professor Eli Avisar

In partnership with: